Le Nostre Pubblicazioni

2018

• Sanna L, Marchesi I, Melone MAB, Bagella L. The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma. Journal of Cellular Physiology, 233(9):6508-6517, 2018.
• Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget 9(27): 18734-18746, 2018. 
• Fiorentino FP, Bagella L, Marchesi I. A New Parameter of Growth Inhibition for Cell Proliferation Assays. Journal of Cellular Physiology, 233(5):4106-41152018, 2018.
• Marchesi I, Sanna L, Fais M, Fiorentino FP, Giordano A, Bagella L. 12-O-Tetradecanoylphorbol-13-acetate and EZH2 inhibition: a novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells. Journal of Cellular Physiology 233(3):2360-2365, 2018.

2017

• Tokgun O, Fiorentino FP, Tokgun PE, Yokota J, Akca H. Design of a Lentiviral Vector for the Inducible Expression of MYC: A New Strategy for Construction Approach. Molecular Biotechnology 59(6):200-206, 2017.

​
2016

• Sanna L, Ortu S, Marchesi I, Bagella P, Fais M, Fiore V, Vidili G, Bagella L, Babudieri S. Evaluation of EZH2 expression in hepatitis B patients. Infectiuos Diseases and Tropical Medicine, 2 (4): e349, 2016.
• Nieddu V, Pinna G, Marchesi I, Sanna L, Asproni B, Pinna GA, Bagella LM, Murineddu G. Synthesis and antineoplastic evaluation of novel unsymmetrical 1,3,4-oxadiazoles. Journal of Medicinal Chemistry, 59 (23), pp 10451–10469, 2016.
• Kato F, Fiorentino FP, Alibés A, Perucho M, Sánchez-Céspedes M, Kohno T, Yokota J. MYCL is a Target of a BET Bromodomain Inhibitor, JQ1, on Growth Suppression Efficacy in Small Cell Lung Cancer Cells. Oncotarget 22;7(47):77378-77388, 2016.
• Fiorentino FP, Tokgün E,  Solé-Sánchez S, Giampaolo S, Tokgün O, Jauset T, Kohno T, Perucho M, Soucek L, Yokota J. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget 7(21):31014-28, 2016.
• Bagella L, Marchesi I. SFK Inhibitors as a New Strategy for RMS Treatment. Chemotherapy: Open Access. 5 (2): 1000189, 2016.
• Marchesi I, Bagella L. Editorial: Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment. World Journal of Clinical Oncology, 7(2):135-48, 2016.

2014

• Marchesi I, Giordano A, Bagella L. Roles of enhancer of zeste homolog 2 From skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis. Cell Cycle, 13(4): 516–27, 2014.

2013​

• Marchesi I, Bagella L. Role of Enhancer of Zeste Homolog 2 Polycomb Protein and Its Significance in Tumor Progression and Cell Differentiation. Chapter 6, Book “Chromatin Remodelling”. InTech; 2013.
• D'Urso V, Doneddu V, Marchesi I, Collodoro A, Pirina P, Giordano A, Bagella L. Sputum analysis: non-invasive early lung cancer detection. Journal of Cellular Physiology, 228(5):945-51, 2013.
• Marchesi I, Nieddu V, Caracciolo V, Maioli M, Gaspa L, Giordano A, Bagella L. Activation and function of murine Cyclin T2A and Cyclin T2B during skeletal muscle differentiation. Journal of Cellular Biochemestry, 114(3):728-34, 2013.
• Fiorentino FP, Marchesi I, Giordano A. On the role of retinoblastoma family proteins in the establishment and maintenance of the epigenetic landscape. Journal of Cellular Physiology, 228(2):276-84, 2013.

2012

• Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. Cell Cycle, 11(20):3828-36, 2012.
• Rizzolio F, Lucchetti C, Caligiuri I, Marchesi I, Caputo M, Klein-Szanto AJ, Bagella L, Castronovo M, Giordano A. Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1. Cell Death and Differentiation, 19(7):1152-61, 2012.
• Fiorentino FP, Giordano A. The tumor suppressor role of CTCF. Journal of Cellular Physiology 227(2):479-92, 2012.

2011

• Fiorentino FP, Macaluso M, Miranda F, Russo A, Bagella L, Giordano A. CTCF and BORIS Regulate Rb2/p130 Gene Transcription: A Novel Mechanism and a New Paradigm for Understanding the Biology of Lung Cancer. Molecular Cancer Research 9(2): 225-33, 2011.
• Perino A, Giovannelli L, Schillaci R, Ruvolo G, Fiorentino FP, Alimondi P, Cefalú E, Ammatuna P. Human papillomavirus infection in couples undergoing in vitro fertilization procedures: impact on reproductive outcomes. Fertility and Sterility 95(5):1845-8, 2011.

2010

• Maioli M, Santaniello S, Montella A, Bandiera P, Cantoni S, Cavallini C, Bianchi F, Lionetti V, Rizzolio F, Marchesi I, Bagella L, Ventura C. Hyaluronan esters drive Smad gene expression and signaling enhancing cardiogenesis in mouse embryonic and human mesenchymal stem cells. PLoS One, 5(11):e15151, 2010.

2009

• Pau A, Murineddu G, Asproni B, Murruzzu C, Grella GE, Pinna GA, Curzu MM, Marchesi I, Bagella L. Synthesis and cytotoxicity of novel hexahydrothienocycloheptapyridazinone derivatives. Molecules, 14(9):3494-508, 2009.
• Fiorentino FP, Symonds CE, Macaluso M, Giordano A. Senescence and p130/Rbl2: a new beginning to the end. Cell Research 19(9):1044-1051, 2009.

​2007

• Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A. The role of Aurora-A inhibitors in cancer therapy. Annals of oncology Suppl 6:vi47-52, 2007.